Results 41 to 50 of about 13,322 (172)

Genetic Diversity of Meningococcal Serogroup B Vaccine Antigens among Carriage Isolates Collected from Students at Three Universities in the United States, 2015–2016

mBio, 2021
The impact of serogroup B meningococcal (MenB) vaccines on carriage is not completely understood. Using whole-genome sequencing data, we assessed the diversity and distribution of MenB vaccine antigens (particularly FHbp) among 1,514 meningococcal ...
Henju Marjuki, How-Yi Chang, Nadav Topaz, Melissa J. Whaley, Jeni Vuong, Alexander Chen, Laurel T. Jenkins, Fang Hu, Susanna Schmink, Adam C. Retchless, Jennifer D. Thomas, Anna M. Acosta, Lucy A. McNamara, Heidi M. Soeters, Sarah Mbaeyi, Xin Wang   +15 more
doaj   +1 more source

Achieving Cancer Prevention Equity: A Policy Analysis of American Cancer Society HPV Vaccination Guidelines

Journal of Advanced Nursing, EarlyView.
ABSTRACT Aim To examine the American Cancer Society's HPV vaccination guidelines through a nursing policy analysis framework, assessing justice and equity outcomes in cancer prevention policy implementation. Background Human papillomavirus vaccination remains critical for cancer prevention, yet persistent health disparities undermine equity goals ...
Grace K. Kyei, Evans K. Kyei, Rockson Ansong   +2 more
wiley   +1 more source

Meningococcal disease. Polysaccharide meningococcal vaccines. The historical aspects and the current state of vaccine development. Report 2

Биопрепараты: Профилактика, диагностика, лечение, 2018
The present article describes clinical signs of meningococcal disease. It justifies the necessity of its vaccine prevention. The article provides with the historical data on the evolution of inoculants from corpuscular inactivated vaccines to modern ...
M. V. Abramtseva, A. P. Tarasov, T. I. Nemirovskaya   +2 more
doaj  

Progress toward the global control of Neisseria meningitidis: 21st century vaccines, current guidelines, and challenges for future vaccine development

Human Vaccines & Immunotherapeutics, 2018
The control of meningitis, meningococcemia and other infections caused by Neisseria meningitidis is a significant global health challenge. Substantial progress has occurred in the last twenty years in meningococcal vaccine development and global ...
A. W. Dretler, N. G. Rouphael, D. S. Stephens   +2 more
doaj   +1 more source

Whole genome analysis of Neisseria meningitidis isolates from invasive meningococcal disease collected in the Czech Republic over 28 years (1993-2020).

PLoS ONE, 2023
Invasive meningococcal disease belongs among the most dangerous infectious diseases in the world. Several polysaccharide conjugate vaccines against serogroups A, C, W and Y are available and two recombinant peptide vaccines against serogroup B (MenB ...
Michal Honskus, Pavla Krizova, Zuzana Okonji, Martin Musilek, Jana Kozakova   +4 more
doaj   +1 more source

Engineered Bacterial Membranes as Next‐Generation Platforms for Cancer Immunotherapy

Small Science, Volume 6, Issue 8, August 2026.
Engineered bacterial membrane platforms, including outer membrane vesicles, bacterial ghosts, genetically engineered membranes, and hybrid bacterial–tumor membranes, integrate tumor antigen presentation with intrinsic immune stimulation. These platforms promote dendritic‐cell activation, T‐cell priming, pyroptosis, and synergistic responses with ...
Hafiza Aasia Malik, Urooj Yousaf Virk, Mohamed Salah Attia, Jenny Wilson, Ming Wei   +4 more
wiley   +1 more source

Optimizing timing of adolescent vaccines: Impact of initiating HPV vaccination before Tdap or meningococcal vaccination on timely completion of the HPV vaccine series

Human Vaccines & Immunotherapeutics, 2023
To explore the impact on timely series completion of initiating the HPV vaccine series prior to other vaccines in the adolescent platform (Tdap or meningococcal vacccines), we created a cohort of children aged 9 in 2015 who were continuously enrolled ...
Sidika Kajtezovic, Jake R. Morgan, Stephen Fiascone, Heather M. Brandt, Rebecca B. Perkins   +4 more
doaj   +1 more source

Low Incidence of Relapses After Vaccination in Anti‐Aquaporin‐4 Antibody‐Positive NMOSD

Annals of Clinical and Translational Neurology, Volume 13, Issue 7, Page 1488-1492, July 2026.
ABSTRACT Patients with neuromyelitis optica spectrum disorder (NMOSD) may experience increased signs and symptoms of their underlying disease when vaccinated against meningococcal disease before receiving complement component 5 inhibitor therapies. This retrospective analysis indicated an overall low relapse incidence (mean [range], 3.3% [0.7%–10.6 ...
Sean J. Pittock, Jin Nakahara, Becky Parks, Kerstin Allen, Sami Fam   +4 more
wiley   +1 more source

Adesão às novas vacinas conjugadas. Vacina anti-meningocócica e anti-pneumocócica.

Acta Médica Portuguesa, 2004
The new conjugate vaccines against group C meningococcal infection and pneumococcal infection were introduced in Portugal in 2001. In 2001/2002, the media published several alarming news on meningococcal disease and there was an increased demand of those
Laurinda De Queirós, Luis Castro, Maria Carmo Ferreira, Guilherme Gonçalves   +3 more
doaj   +1 more source

Complement Inhibition in the Clinic: Are We Doing Enough to Protect Patients From Infection?

European Journal of Immunology, Volume 56, Issue 7, July 2026.
Excessive complement activation is implicated in a broad range of diseases. Therapeutic approaches targeting the complement cascade, from pathway‐selective inhibition to terminal blockade, can effectively control disease activity. However, increasing degrees of complement inhibition are associated with a heightened susceptibility to bacterial, viral ...
Serena Bettoni, Ebba Qviberg, Edward Chaloner, Hayley Lavender, Maisem Laabei   +4 more
wiley   +1 more source